The estimated Net Worth of Petrus Bekker is at least 3.92 百万$ dollars as of 11 July 2017. Petrus Bekker owns over 76,013 units of ChemoCentryx Inc stock worth over 3,741,408$ and over the last 13 years Petrus sold CCXI stock worth over 179,100$.
Petrus has made over 26 trades of the ChemoCentryx Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Petrus exercised 76,013 units of CCXI stock worth 532,091$ on 11 July 2017.
The largest trade Petrus's ever made was exercising 76,013 units of ChemoCentryx Inc stock on 11 July 2017 worth over 532,091$. On average, Petrus trades about 12,595 units every 55 days since 2012. As of 11 July 2017 Petrus still owns at least 71,964 units of ChemoCentryx Inc stock.
You can see the complete history of Petrus Bekker stock trades at the bottom of the page.
Petrus's mailing address filed with the SEC is C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW, CA, 94043.
Over the last 13 years, insiders at ChemoCentryx Inc have traded over 355,980,520$ worth of ChemoCentryx Inc stock and bought 3,166,975 units worth 19,475,662$ . The most active insiders traders include Plc Gsk、Rishi Gupta、(International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of 4,175,785$. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth 216,092$.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
ChemoCentryx Inc executives and other stock owners filed with the SEC include: